Oxaliplatin

Oxaliplatin
Clinical data
Trade names	Eloxatin
AHFS/Drugs.com	Monograph
MedlinePlus	a607035
License data	US DailyMed: Oxaliplatin;
Routes of; administration	Intravenous
ATC code	L01XA03 (WHO) ;
Legal status
Legal status	AU: S4 (Prescription only); US: ℞-only;
Pharmacokinetic data
Bioavailability	Complete
Elimination half-life	~10 – 25 minutes
Excretion	Kidney
Identifiers
	IUPAC name [(1R,2R)-cyclohexane-1,2-diamine](ethanedioato-O,O')platinum(II);
CAS Number	61825-94-3 ;
PubChem CID	77994;
DrugBank	DB00526 ;
ChemSpider	8062727 ;
UNII	04ZR38536J;
KEGG	D01790 ;
ChEMBL	ChEMBL414804 ;
PDB ligand	1PT (PDBe, RCSB PDB);
CompTox Dashboard (EPA)	DTXSID701125309 DTXSID0036760, DTXSID701125309 ;
ECHA InfoCard	100.150.118
Chemical and physical data
Formula	C8H14N2O4Pt
Molar mass	397.294 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES O1C(=O)C(=O)O[Pt-2]12[NH2+]C0CCCCC0[NH2+]2;
	(what is this?) (verify)

Oxaliplatin, sold under the brand name Eloxatin among others, is a cancer medication (platinum-based antineoplastic class) used to treat colorectal cancer.^[4] It is given by infusion into a vein.^[4]

Common side effects include numbness, feeling tired, nausea, diarrhea, and low blood cell counts.^[4]^[5] Other serious side effects include allergic reactions.^[5]^[4] Use in pregnancy is known to harm the baby.^[4] Oxaliplatin is in the platinum-based antineoplastic family of medications.^[6] It is believed to work by blocking the duplication of DNA.^[4]

Oxaliplatin was patented in 1976 in Japan and approved for medical use in 1996 in Europe.^[7] It is on the 2023 World Health Organization's List of Essential Medicines.^[8]

^ "Prescription medicines: registration of new generic medicines and biosimilar medicines, 2017". Therapeutic Goods Administration (TGA). 21 June 2022. Retrieved 30 March 2024.
^ "Eloxatin- oxaliplatin injection, solution, concentrate". DailyMed. 22 October 2019. Retrieved 26 May 2022.
^ Ehrsson H, Wallin I, Yachnin J (2002). "Pharmacokinetics of oxaliplatin in humans". Medical Oncology. 19 (4): 261–265. doi:10.1385/MO:19:4:261. PMID 12512920. S2CID 1068099.
^ ^a ^b ^c ^d ^e ^f "Oxaliplatin". The American Society of Health-System Pharmacists. Archived from the original on 21 December 2016. Retrieved 8 December 2016.
^ ^a ^b Oun R, Moussa YE, Wheate NJ (May 2018). "The side effects of platinum-based chemotherapy drugs: a review for chemists". Dalton Transactions. 47 (19): 6645–6653. doi:10.1039/c8dt00838h. PMID 29632935.
^ Apps MG, Choi EH, Wheate NJ (August 2015). "The state-of-play and future of platinum drugs". Endocrine-Related Cancer. 22 (4): R219 – R233. doi:10.1530/ERC-15-0237. hdl:2123/24426. PMID 26113607.
^ Fischer J, Ganellin CR (2006). Analogue-based Drug Discovery. John Wiley & Sons. p. 513. ISBN 9783527607495. Archived from the original on 20 December 2016.
^ World Health Organization (2023). The selection and use of essential medicines 2023: web annex A: World Health Organization model list of essential medicines: 23rd list (2023). Geneva: World Health Organization. hdl:10665/371090. WHO/MHP/HPS/EML/2023.02.